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AbsTRACT
background: Fibrinolysis is often used in the treatment of 
acute coronary syndromes with ST segment elevation (STEMI). 
Major cardiac outcomes were reduced with antiplatelet 
therapy intensification, but with increased risk of bleeding. 
Our objective was to assess the risk of vascular bleeding in 
patients undergoing early percutaneous coronary intervention 
after thrombolysis. Methods: Between February 2010 and 
December 2011, five public emergency rooms in the city of 
São Paulo and the Emergency Health Care Service (Serviço de 
Atendimento Móvel de Urgência – SAMU) used tenecteplase 
(TNK) to treat patients with STEMI. Patients were referred to 
a single tertiary hospital and were submitted to early cardiac 
catheterization during hospitalization. All examinations were 
performed via the femoral artery and BARC criteria were used 
to classify bleeding. Results: We evaluated 199 patients, of 
whom 193 had no bleeding of vascular origin (group 1) and 
6 (3%) developed this complication (group 2). The median 
time between the administration of the fibrinolytic agent and 
catheterization was 24 hours in group 1 and 14.7 hours in 
group 2. According to BARC criteria, 1 patient had type 3a 
bleeding (hematoma in the inguinal region with a hemoglobin 
decrease of 3-5 g/dL), 2 patients had type 3b bleeding (1 not 
related to vascular access and 1 retroperitoneal hematoma 
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REsUMo
Complicações Vasculares em Pacientes submetidos  
a Intervenção Coronária Percutânea Precoce  
por Via Femoral após Fibrinólise com  
Tenecteplase: Registro de 199 Pacientes
Introdução: A fibrinólise é frequentemente utilizada no trata-
mento das síndromes coronárias com supradesnivelamento do 
segmento ST (SCCSST). Desfechos cardíacos maiores foram 
reduzidos com a intensificação do tratamento antiplaquetário, 
porém com aumento do risco de sangramento. Nosso objetivo 
foi avaliar o risco de sangramentos de origem vascular em 
pacientes submetidos a intervenção coronária precoce pós-
-trombólise. Métodos: Entre fevereiro de 2010 e dezembro de 
2011, 5 prontos-socorros municipais da cidade de São Paulo 
e o Serviço de Atendimento Móvel de Urgência (SAMU) uti-
lizaram tenecteplase (TNK) para tratamento de pacientes com 
SCCSST. Os pacientes foram encaminhados a um único hospital 
terciário e submetidos a cateterismo cardíaco precoce durante 
a internação. Todos os exames foram realizados por via femo-
ral e os critérios do BARC foram utilizados para a classificação 
dos sangramentos. Resultados: Foram avaliados 199 pacientes, 
dos quais 193 não apresentaram sangramento de origem vascular 
(grupo 1) e 6 (3%) evoluíram com essa complicação (grupo 2). 
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with a hemoglobin decrease ≥ 5 g/dL) and the remaining 
patients had type 1 bleeding (small inguinal hematomas). 
Blood transfusions were required in 2 patients. None of the 
patients died due to vascular complications after the interven-
tion. Conclusions: In our study, early catheterization via the 
femoral artery as part of a pharmaco-invasive strategy, using 
TNK as a fibrinolytic agent, had a low vascular bleeding rate, 
comparable to that of elective angioplasties.
 
 
 
 
 
 
 
DEsCRIPToRs: Fibrinolysis. Angioplasty. Myocardial infarc-
tion. Hemorrhage.
A mediana de tempo entre a administração do fibrinolítico e 
o cateterismo foi de 24 horas no grupo 1 e de 14,7 horas no 
grupo 2. Segundo os critérios do BARC, 1 paciente apresentou 
sangramento do tipo 3a (hematoma em região inguinal com 
queda de hemoglobina de 3-5 g/dL), 2 pacientes apresentaram 
sangramento do tipo 3b (1 não relacionado ao acesso vascular 
e 1 hematoma de retroperitônio, com queda de hemoglobina 
≥ 5 g/dL), e os demais apresentaram sangramentos do tipo 1 
(pequenos hematomas em região inguinal). Nesse grupo foram 
necessárias duas hemotransfusões. Nenhum paciente teve óbito 
relacionado à complicação vascular pós-intervenção. Conclusões: 
Em nosso estudo, a cateterização precoce via femoral como 
parte de uma estratégia fármaco-invasiva, utilizando TNK como 
fibrinolítico, apresentou baixa taxa de sangramentos de origem 
vascular, comparável à das angioplastias eletivas.
DEsCRIToREs: Fibrinólise. Angioplastia. Infarto do miocárdio. 
Hemorragia.
T he coronary syndromes that course with ST-segment elevation myocardial infarction (STEMI) remain an important cause of morbidity and mortality. In 
this group of patients, the prognosis and incidence of 
major adverse events are directly associated with the 
interval between symptom onset and flow restoration 
in the coronary lesion; reperfusion therapy remains as 
the basis of treatment.
Fibrinolytic agents initiated the ‘era of reperfusion’, 
promoting the lysis of the occlusive thrombus and 
achieving the reduction of infarcted area, ventricular 
function improvement and increased survival.1 Percuta-
neous coronary intervention (PCI) was later established 
as the method of choice for the restoration of antegrade 
coronary flow, providing higher rates of reperfusion 
(90% vs. 50% with fibrinolytic agents) and additional 
reductions in major cardiovascular outcomes.2,3 The 
combined use of these strategies follows restricted 
indications in scenarios in which it was proven to be 
safe and effective: PCI after fibrinolysis without success 
(rescue) and early PCI between three and 24 hours after 
successful chemical reperfusion (drug-invasive strategy).4
Additionally, the use of modern antithrombotic 
pharmacotherapy (oral platelet antiaggregants, glyco-
protein IIb/IIIa inhibitors, and  antithrombotic agents) 
has resulted in additional reductions in cardiovascular 
mortality and the recurrence of ischaemic events.5 
However, the indubitable benefit of these associations 
is counterbalanced by the inherent increased risk of 
bleeding, the major non-cardiac complication in patients 
treated for acute myocardial infarction (AMI).6
Hemorrhagic complications, whether or not related 
the vascular puncture site, are associated with a higher 
incidence of cerebrovascular events, AMI, intrastent 
thrombosis, and  death,7 and they currently occur with 
similar frequency to that of ischemic complications. The 
reduction in bleeding episodes translates into improved 
survival, shorter hospital stay, and lower costs, justifying 
the current emphasis on the identification of predisposing 
factors and prophylaxis of bleeding episodes.7
In this study, patients diagnosed with STEMI who 
were treated with fibrin-specific thrombolytic therapy 
and who underwent early coronary angiography and PCI 
via the femoral artery were evaluated for the incidence 
of bleeding of vascular origin.
Methods
Patients and procedures
This was an observational study with prospective 
data collection, conducted between November of 2009 
and January of 2012. In this study, 199 patients who met 
the diagnostic criteria for AMI, with electrocardiographic 
evidence of ST-segment elevation or left bundle branch 
block (new or presumably new), were initially treated 
at a network of municipal emergency departments or 
the Mobile Emergency Service (Serviço de Atendimento 
Móvel de Urgência – SAMU) and then transferred to 
Hospital São Paulo, Universidade Federal de São Paulo 
(UNIFESP). These patients were treated with tenecteplase 
(TNK) and underwent early coronary angio graphy and PCI 
when necessary, exclusively through the femoral artery.
Patients were consecutively included  in this study, 
divided into two groups (according to the presence or 
absence of bleeding of vascular origin) and evaluated 
for the incidence and predictors of these complications. 
All patients received loading doses of 300 mg of ace-
tylsalicylic acid and 300 mg or 600 mg of clopidogrel 
during the primary care or upon arrival at the tertiary 
hospital. The antithrombin agent of choice during PCI 
was unfractionated heparin at a dose of 100 U/kg (or 
70 U/kg in those treated with glycoprotein IIb/IIIa in-
hibitors). The size of the arterial sheaths used was left 
to the surgeon’s discretion. Patients undergoing PCI 
received only bare-metal stents, which were provided 
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by the Brazilian Unified Health System (Sistema Único 
de Saúde – SUS).
Hemostasis after removing the introducer was per-
formed exclusively by manual compression, respecting 
an interval of four to six hours after administration of 
unfractio nated heparin in the emergency room.
definitions
Bleeding episodes were classified according to the 
criteria established by the Bleeding Academic Research 
Consortium (BARC)7 in 2011 (Table 1).
Obesity was defined as body mass index (BMI) > 35 
kg/m² and chronic renal disease by creatinine clearance 
≤ 60 mL/min, estimated by the Cockroft-Gault equation. 
Peripheral vascular disease, dyslipidaemia, diabetes mellitus, 
and hypertension were identified as part of the pathological 
history or were diagnosed du ring hospitalization.
statistical analysis
The prospectively collected data were stored in a 
spreadsheet database (Excel®, Microsoft Corporation, 
Redmond, USA) and submitted to statistical analysis 
using the Statistical Package for Social Sciences (SPSS), 
release 14.0.
Continuous variables were expressed as means 
and standard deviations, and categorical variables were 
expressed as absolute numbers and percentages. Cate-
gorical variables were compared by Fisher’s exact test 
or the chi-squared test, and continuous variables were 
compared by Student’s t-test. For variables without normal 
distribution, the median was compared between groups.
A multivariate logistic regression model, adjusted 
for the interaction between age and diabetes mellitus 
and that between diabetes mellitus and chronic renal 
disease, was used to identify possible independent 
predictors of hemorrhagic vascular complications. Odds 
ratios (ORs) and their confidence intervals (95% CIs) 
were calculated to quantify the effects. The variables 
used in this model were the clinical variables age, 
gender, diabetes, arterial hypertension, peripheral vas-
cular disease, chronic renal disease, dyslipidaemia, and 
obesity. P-values < 0.05 were considered significant 
for all analyses.
Results
Of the 199 patients evaluated, 193 (97%) had no 
bleeding of vascular origin (group 1), and six patients 
(3%) had such complications (group 2). In 19 patients 
(9%), the intervention was indicated after thrombolytic 
TAbLE 1 
Classification of the bleeding Academic Research Consortium (bARC)
Type 0 Absence of bleeding.
Type 1 Minor bleeding, not requiring medical attention or hospitalisation.
Type 2 Any sign of bleeding that does not meet the criteria of types 3, 4, or 5, but meets at least one of the 
following criteria: 
- need for non-surgical medical intervention; 
- need for hospitalisation or increased level of care; 
- need for immediate clinical evaluation. 
Type 3 
Type 3a Bleeding associated with a decrease in haemoglobin of 3–5 g/dL or need for blood transfusion.
Type 3b Bleeding associated with a decrease in haemoglobin ≥ 5 g/dL, cardiac tamponade, need for surgical 
control of bleeding (except dental/nasal/skin/haemorrhoid), or  need for vasoactive drugs.
Type 3c Intracranial bleeding (except for micro-bleeding or haemorrhagic transformation; includes intraspinal 
bleeding); subcategories confirmed by autopsy, imaging, or lumbar puncture; or intraocular bleeding 
with vision impairment.
Type 4 Bleeding related to coronary artery bypass: perioperative intracranial bleeding within 48 hours; 
reoperation after closure of sternotomy to control bleeding; transfusion ≥ 5 packed red blood cells 
within a 48-hour period; chest tube bleeding ≥ 2 L in 24 hours.
Type 5 Fatal bleeding. 
Type 5a Probable fatal bleeding: clinical suspicion not confirmed by autopsy or imaging. 
Type 5b Definitive fatal bleeding: active bleeding or confirmed by autopsy or imaging methods.
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therapy failure (rescue PCI); of these patients, only one 
had hematoma at the puncture site and a decrease in 
hemoglobine of 4.1 g/dL. The other patients underwent 
elective coronary angiography at a mean of 19 ± 4 hours 
(ranging from three hours to 3.5 days) after thrombolytic 
therapy. The median time between the administration of 
the fibrinolytic agent and PCI was 24 hours in group 
1 and 14.7 hours in group 2.
Regarding clinical characteristics, group 2 patients 
were older (57 ± 11 years vs. 69 ± 11.7 years, P = 0.01) 
and had a higher prevalence of chronic renal disease 
(6% vs. 67%, P = 0.01). The prevalence of hypertension, 
diabetes mellitus, obesity and peripheral vascular disease 
was similar between groups (Table 2).
Only one patient in group 2 received glycoprotein 
IIb/IIIa inhibitors during the procedure. 6-F and 7-F 
sheaths were used, at the surgeon’s discretion. In group 
1, 7-F sheaths were used in 16 of 193 patients (8%), 
compared to four of the six patients (67%) in group 
2, and a significant increase in the risk of bleeding 
complications was observed with the use of larger 
sheaths (P = 0.001).
In group 2, three patients experienced bleeding 
related to an arterial puncture site categorised as type 
1. The other three patients had more severe bleeding: 
one had a large inguinal hematoma associated with a 
decrease in hemoglobin of 4.1 g/dL; the second patient 
had a hematoma in the pretibial region with a decrease 
in hemoglobin of 5.9 g/dL, possibly related to trauma 
in the days prior to AMI; the last patient had a retro-
peritoneal hematoma with a decrease in hemoglobin 
of 7.8 g/dL (Table 3).
Only two patients in group 2 (patients 3 and 4, 
Table 3) required transfusion of blood products. None 
of the patients died of vascular complications; how-
ever, there was one death in group 2 resulting from 
cardiogenic shock (patient 3).
In multivariate regression analysis, after correcting 
for the interaction between diabetes mellitus and 
chronic renal disease, the only variable that remained 
associated with the presence of hemorrhagic vascular 
complications was chronic renal disease (OR: 18.4; 
95% CI: 1.12–299.61; P = 0.04) (Table 4).
discussion
Current recommendations for PCI after fibrinolytic 
therapy are rescue PCI (class IIa, level of evidence B, 
in the ACC/AHA/SCAI guidelines of 2011, and class I, 
level of evidence A, in the guidelines of the European 
Society of Cardiology, 2012); elective and systematic PCI 
performed between three and 24 hours after effective 
fibrinolysis (class IIa, level of evidence A, ACC/AHA/
SCAI guidelines, and class I, level of evidence A, in 
the guidelines of the European Society of Cardiology); 
and PCI in patients with evidence of clinical ischemia 
or in functional tests (class IIa, level of evidence B, in 
the ACC/AHA/SCAI guidelines).4,8
In stable patients submitted to successful chemistry 
reperfusion, the use of systematic and early invasive 
stratification within the first 24 hours (drug-invasive 
strategy) has been associated with reduced incidences 
of reinfarction and recurrent ischemic events without 
significantly increasing the rates of vascular compli-
cations. However, very early coronary angiography 
(less than three hours after administration of throm-
bolytic agent) results in high rates of ischemic and 
hemorrhagic complications and should be reserved for 
cases of treatment failure.4,9–11
TAbLE 2 
Demographic and clinical characteristics of patients undergoing fibrinolysis  
and catheterisation/early percutaneous coronary intervention 
Group 1
(n = 193)
Group 2
(n = 6) P
Male gender, n (%) 133 (70) 4 (67) 0.97
Age, years 57 ± 11 69 ± 11.7 0.01
Systemic arterial hypertension, n (%) 124 (64) 5 (83) 0.33
Diabetes mellitus, n (%) 48 (25) 1 (17) 0.64
Peripheral vascular disease, n (%) 15 (8) 1 (17) 0.43
Chronic renal disease, n (%) 12 (6) 4 (67) 0.01
Obesity, n (%) 69 (36) 1 (17) 0.33
n = number of patients.
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Ample evidence supports the use of a drug-invasive 
approach. In the Trial of Routine ANgioplasty and 
Stenting after Fibrinolysis to Enhance Reperfusion in 
Acute Myocardial Infarction (TRANSFER-AMI), 1,030 
patients with high-risk STEMI were randomized to ur-
gent PCI performed four hours after administration of 
TNK or standard treatment (subsequently transferred to 
elective coronary angiography or rescue PCI, if neces-
sary). The composite endpoint of death, reinfarction, 
recurrent ischemia, heart failure or shock at 30 days 
occurred in 10.6% of the early PCI group and in 16.6% 
of the standard treatment group (OR: 0.537; 95% CI: 
0.368–0.783; P = 0.0013).12 There was no significant 
increase in the rate of bleeding in the early PCI group. 
In the Combined Abciximab Reteplase Stent Study in 
Acute Myocardial Infarction (CARESS-in-AMI), 600 
patients were randomized to early angiography three 
hours after fibrinolytic therapy or standard therapy. The 
combined endpoint of death, reinfarction and refrac-
tory ischemia at 30 days occurred in 4.4% of the early 
PCI group and in 10.7% of the standard group (P = 
0.004); and rescue PCI was necessary in 30.3% of 
cases. Minor bleeding occurred more frequently in the 
early PCI group (10.8% vs. 4%, P = 0.002), but there 
was no significant increase in major bleeding episodes 
(3.4% vs. 2.3%, P = 0.47).13 In the Grupo de Análisis 
de la Cardiopatía Isquémica Aguda (GRACIA-2) study, 
the use of TNK followed by systematic PCI within a 
range of three to 12 hours (mean 4.6 hours) was not 
found to be inferior to primary PCI regarding the major 
outcomes, and there was no significant increase in the 
rate of bleeding.14
TAbLE 3 
Characteristics of patients with bleeding of vascular origin in percutaneous coronary  
intervention after thrombolysis
Case Age Risk factors
Time  
lysis-PCI 
(hrs)
bARC7 
classification Type of complication
Difference in 
haemoglobin, pre- 
and post-event (g/dL)
1 72 Obesity, DLP,  
PVD, CRD
92 3b Tibial haematoma 5.9
2 65 SAH 29.6 1 Inguinal haematoma 1
3 53 SAH, DM, DLP, CRD 5.5 3a Inguinal haematoma 4.1
4 62 SAH, DLP 3.25 3b Retroperitoneal haematoma 7.8
5 78 SAH, CRD 3.3 1 Inguinal haematoma 1.2
6 84 SAH, CRD 24 1 Inguinal haematoma 2.1
BARC = Bleeding Academic Research Consortium; DLP = dyslipidaemia; DM = diabetes mellitus; PVD = peripheral vascular disease; 
SAH = systemic arterial hypertension; PCI = percutaneous coronary intervention; CRD = chronic renal disease.
TAbLE 4 
Results of the logistic regression to determine the risk of bleeding of vascular origin  
in percutaneous coronary intervention after thrombolysis 
oR 95% CI P
Age 1.07 0.94–1.22 0.29
Male gender 0.29 0.01–9.88 0.49
Body mass index 1.02 0.67–1.53 0.93
Diabetes mellitus 0 0 1
Systemic arterial hypertension 4.35 0.15–124.21 0.39
Peripheral vascular disease 1.80 0.02–131.09 0.79
Chronic renal disease 18.4 1.12–299.61 0.04
95% CI = 95% confidence interval; OR = odds ratio.
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The association between antithrombotic drugs and 
revascularization procedures has proven effective in the 
prevention of recurrent ischemic events and death in 
acute coronary syndromes (ACS). This combination is, 
however, associated with an increased risk of bleed-
ing and vascular complications, especially in older 
patients, those using multiple antithrombotic therapy, 
and those submitted to early revascularization.15 In high-
risk subgroups, the prevalence of major hemorrhagic 
complications during treatment reaches 5%, close to 
that of ischaemic events.
Factors such as advanced age, female gender, chronic 
renal disease, low BMI, and  the need for invasive 
procedures have been strongly implicated as predictors 
of vascular complications. Elderly patients present with 
progressive deposition of amyloid and collagen in the 
arterial tunica media, resulting in vascular frailty and 
greater tendency to vascular complications. Women 
have lower BMI and lower creatinine clearance than 
men and are therefore more susceptible to relatively 
higher doses of antithrombotic agents and bleeding. 
Additional contributing factors to vascular complications 
are smaller vascular diameter and possible differences 
in response to antithrombotics.6 In turn, patients with 
chronic nephropathy more often exhibit a pattern of 
diffuse vascular disease, in addition to being more 
often exposed to higher (uncorrected) doses of drugs. 
The higher prevalences of anemia (reduced synthesis of 
erythropoietin) and platelet dysfunction in these patients 
also contribute to these complications.
When analysing the impact of bleeding complications 
on the prognosis of patients with ACS, Eikelboom et 
al.16 demonstrated that the occurrence of major bleeding 
was associated with a five-fold increased risk of death 
at 30 days and that one in three patients who had 
bleeding episodes and died developed an AMI during 
hospitalization. Ndrepepa et al.5 analysed 12,459 patients 
undergoing PCI who were enrolled in six randomized 
studies on the correlation between bleeding episodes 
and mortality in one year. They found that bleeding 
episodes classified as BARC ≥ 2 were associated with 
significantly increased mortality in one year (OR: 2.72; 
95% CI: 2.03–3.63).
Several hypotheses have been posited to justify this 
association between bleeding and major cardiovascular 
outcomes. These complications are possibly associated 
with hypotension, platelet activation, and decreased tissue 
oxygen supply (hypoperfusion or decreased haemoglobin) 
due to bleeding and the deleterious effects of blood 
transfusion. Additionally, the presence of bleeding requires 
the suspension of several drugs with proven benefits in 
increasing survival, such as antiplatelets and beta block-
ers, predisposing the patient to intrastent thrombosis, AMI, 
recurrent angina, acute ischaemic stroke, and death.16
Most bleeding episodes in patients with ACS 
undergoing PCI are iatrogenic, attributable to arterial 
puncture (more frequent in the femoral artery), ranging 
from a small subcutaneous haematoma free of clinical 
relevance to a fatal retroperitoneal haematoma. The 
femoral artery remains the most widely used means 
of access for interventional procedures. The alternative 
use of radial access has provided increased safety and 
comfort for patients.6
Jolly et al.,17 in a randomized clinical trial com-
paring radial vs. femoral access in patients with ACS 
undergoing PCI, found no differences between the two 
groups in terms of major cardiovascular outcomes, 
but the radial approach was safer, with lower rates of 
vascular complications.
In the RadIal Vs femorAL access for coronary 
intervention (RIVAL) study,18 published in 2011, 7,021 
patients from 32 countries with a diagnosis of ACS 
were randomized to coronary angiography with possible 
intervention by radial access vs. femoral access. There 
were no differences regarding the primary composite 
endpoint of death, AMI, cerebrovascular disease and 
major bleeding (not related to revascularization) at 
30 days (3.7% vs. 4%, P = 0.5). However, radial 
access significantly reduced the secondary endpoint of 
complications related to vascular access (P < 0.001). 
In the Radial versus Femoral Randomized Investigation 
in ST-segment Elevation Acute Coronary Syndrome 
(RIFLE-STEACS) study,19 published in 2012, 1001 pa-
tients with STEMI undergoing primary or rescue PCI 
were randomized to radial vs. femoral access. The 
primary outcome analysis, a combination of death, 
cerebrovascular disease, acute myocardial infarction, 
target vessel revascularization, and bleeding, was sig-
nificantly lower in the radial group (13.6% vs. 21%, 
P = 0.003). Bleeding episodes occurred in 10% of 
patients, with the highest incidence in the femoral 
group (12.2% vs. 7.8%, P = 0.026). This difference 
was primarily due to a lower rate of bleeding related 
to puncture site in the radial group (2.6% vs. 6.8%, 
P = 0.002). In the evaluation of secondary outcomes, 
there was a significant reduction in mortality at 30 
days in the radial group (5.2% vs. 9.2%, P = 0.002). 
In a meta-analysis that included 761,919 patients 
from 76 studies (15 randomized and 61 observational 
studies) comparing radial and femoral routes for PCI, 
Bertrand et al.20 demonstrated significant reductions of 
78% of bleeding and 80% of blood transfusions with 
the use of radial access. It is noteworthy that these 
studies were conducted in institutions with extensive 
experience with radial access, a situation that cannot 
always be reproduced, especially in laboratories where 
specialists are educated and trained and individual 
experience varies with training. In the RIVAL study, 
centers with higher volumes of PCI through the radial 
access route obtained a greater benefit. These centers 
had lower rates of crossover to femoral access, of 
major vascular complications, and  of the composite 
outcome of death, AMI, and  cerebrovascular disease. 
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This effect was not reproduced in the centers with 
smaller volumes.
When using the femoral approach, the use of 
vascular occlusion devices has translated into a greater 
impact on the prevention of major bleeding episodes, 
in spite of substantially increased costs. In the present 
study, hemostasis was achieved by manual compres-
sion in all cases.
Bleeding of undetermined origin, detected by de-
creases in hemoglobin and hematocrit (with or without 
blood transfusion), is also relevant. In one randomized 
study, this type of event accounted for almost half of 
the bleedings not associated with vascular access. 
Verheugt et al.15 demonstrated that bleedings not as-
sociated with the puncture site cause a two-fold higher 
annual mortality than that observed for arterial-access 
bleedings (and four times higher than in individuals 
without bleeding).
The present study evaluated patients undergoing 
early drug-invasive strategy through femoral access, 
and a low incidence of hemorrhagic vascular compli-
cations was observed (3%), similar to that observed in 
elective interventions,21 demonstrating the safety of this 
approach. In their analysis of 4,595 patients under going 
PCI, either elective or emergency, in which 95% of 
the procedures were performed via the femoral artery 
with 6-F sheaths, Zanatta et al.21 observed a vascular 
complication rate of 3.3%.
When comparing the groups, although the median 
time between fibrinolytic use and the percutaneous 
procedure was higher in group 1 (24 hours vs. 14.7 
hours), both were within the safe range of three and 
24 hours, and therefore there was no evidence of an 
increase in major bleeding complications with previous 
use of fibrinolytics.4,9
In 83% (5/6) of cases in this series, complications 
were related to vascular puncture site, in accordance 
with the literature. Half of the bleeding complications 
were categorized as BARC type 1, and no deaths from 
vascular causes were observed. In fact, BARC type 1 
bleeding episodes have good prognosis, with morta-
lity at 30 days and one year similar to that found in 
patients who have not experienced bleeding.22 In a 
patient classified as BARC type 3b, the occurrence of 
extensive hematoma in the pretibial region was not 
associated with the vascular puncture and was most 
likely caused by closed vascular trauma that occurred 
before the fibrinolysis, which resulted in a decrease in 
haemoglobin of 5.9 g/dL, but with no clinical repercus-
sion or need for blood transfusion (prior haemoglobin 
of 16.3 g/dL).
Only one death occurred in group 2, in a patient 
admitted with extensive anterior STEMI who developed 
cardiogenic shock, a condition that, alone, causes high 
morbidity and mortality. Early angiography (5.5 hours), 
as rescue therapy, evidenced an acute occlusion in the 
left main coronary artery, and a PCI was immediately 
performed using an intra-aortic counterpulsation bal-
loon through the femoral artery. This patient had ex-
tensive bleeding at the puncture site, with a decrease 
in haemoglobin of 4.1 g/dL, which was subsequently 
controlled with blood transfusion and vasopressor drugs. 
The patient progressed to death secondary to refractory 
cardiogenic shock two days after the intervention.
In the bleeding group, the greater number of elderly 
patients and patients with chronic nephropathy were 
identified as possible predictors of vascular complica-
tions and bleeding. After the multivariate analysis, 
only chronic renal disease remained a significant and 
independent risk factor for these conditions. Charac-
teristics repeatedly associated with increased vascular 
complications in the literature, such as female gender 
and low BMI, were not identified in the present study, 
possibly because of the small sample size.
study limitations
The present study had the following limitations: its 
re trospective and observational nature; its performance 
in a single centre, which is a training and teaching 
facility in interventional cardiology; the small sample 
size; and the lack of late follow-up. The non-inclusion 
of procedure-related variables (sheath size, procedure 
time, use of intra-aortic balloon) and the small number 
of primary outcomes (six events) represented limiting 
factors in the multivariate analysis, which was performed 
to identify possible predictors for such events.
Although this center meets the recommendation 
for early catheterization (within 24 hours), logistic 
complications may delay the implementation of the 
procedure. In the present study, two patients with 
vascular bleeding underwent the procedure after the 
initial period of 24 hours.
The present results do not necessarily apply to 
populations using other fibrinolytic agents.
conclusions
In the present study, early catheterization via femoral 
access as part of a drug-invasive strategy, using TNK as 
a fibrinolytic agent, showed a low rate of bleeding of 
vascular origin, comparable to that of elective angioplas-
ties, in agreement with several multicenter studies and 
based on current guidelines.
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